Editorial, J Addict Behav Ther Rehabil Vol: 0 Issue: 0
Running Over the Same Old Ground: What�s Missing in Cocaine Clinical Pharmacotherapy Trials?
|Jennifer G. Plebani*|
|University of Pennsylvania, USA|
|Corresponding author : Jennifer G. Plebani, PhD
Research Assistant Professor of Psychology in Psychiatry, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, PA 19104, USA
Tel: +1-215-222-3200; Fax: +1- 215-386-5106
|Received: June 17, 2012 Accepted: June 19, 2012 Published: June 21, 2012|
|Citation: Melvin A (2012) Running Over the Same Old Ground: What’s Missing in Cocaine Clinical Pharmacotherapy Trials?. J Addict Behav Ther Rehabil 1:1. doi:10.4172/2324-9005.1000e102|
Running Over the Same Old Ground: What’s Missing in Cocaine Clinical Pharmacotherapy Trials?
In over two decades of cocaine treatment research, countless pharmacotherapies have been tested, without a single medication approved for the treatment of cocaine dependence. A short and entirely incomplete list of tested medications includes: olanzapine, valproate, coenzyme Q10, L-carnitine, cabergoline, reserpine, tiagabine, amantadine, propranolol, selegiline, modafinil, sertraline, disulfiram, baclofen, and citicoline. Setting aside the very real possibility that none of the medications tested to date is actually efficacious for treating cocaine dependence, there are three main issues that appear to have potentially hindered accurate findings in such studies.